4 - Polyrizon Ltd. (0001893645) (Issuer)

4 - Polyrizon Ltd. (0001893645) (Issuer)

4 - Polyrizon Ltd. (0001893645) (Issuer)

4 - Polyrizon Ltd. (0001893645) (Issuer)

4 - Polyrizon Ltd. (0001893645) (Issuer)

4 - Polyrizon Ltd. (0001893645) (Issuer)

3 - Polyrizon Ltd. (0001893645) (Issuer)

3 - Polyrizon Ltd. (0001893645) (Issuer)

3 - Polyrizon Ltd. (0001893645) (Issuer)

3 - Polyrizon Ltd. (0001893645) (Issuer)

RAANANA, ISRAEL, April 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the closing of its previously announced registered direct offering and concurrent private placement with a single institutional investor. The Company issued Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also issued to the same investor pre-funded and investor warrants. Aggregate gross proceeds to the Company from both transactions were approximately $3.5 million. The transactions closed on April 8, 2026. The transacti

RAANANA, ISRAEL, April 07, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has entered into definitive agreements with a single institutional investor for the purchase and sale of its Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investor pre-funded and investor warrants. Aggregate gross proceeds to the Company from both transactions are expected to be approximately $3.5 million. The transactions consisted of the sale of 388,888 Units (or Pre-Funded Uni

Raanana, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, provided 2025 and recent a business update. "Polyrizon has delivered significant progress across its innovative nasal programs, including key regulatory advancements with the FDA, preparation for potential human clinical trials, and valuable medical collaborations, all powered by a strong cash position and a debt-free balance sheet," said Tomer Izraeli, chief executive officer of Polyrizon. Key Highlights of Polyrizon's Achievements in 2025 and Recent Highlights: As of December 31, 2025, t

Raanana, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the "SEC"). The report is available on the SEC's website, at www.sec.gov and Polyrizon's Investor Relations website, at https://investor.polyrizon-biotech.com/. Shareholders can obtain copies of Polyrizon's Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Polyrizon's Investor Relat

The Company signed a non-binding MOU with shareholders of Colugo. Colugo's customer include the Israel Defense Forces, national first responders organizations and commercial companies Raanana, Israel, March 24, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the signing of a non-binding Memorandum of Understanding ("MOU") with shareholders of Colugo Systems Ltd. ("Colugo"), an innovative Israeli developer of advanced electric Vertical Take-Off and Landing (eVTOL) drone systems, for the acquisition of up to 20% stake in Colugo. Established in 2016,

Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the signing of an agreement with a leading global preclinical Contract Research Organization (CRO), a recognized expert in biocompatibility and regulatory-compliant testing. This agreement forms part of Polyrizon's ongoing efforts to advance its clinical development program, which also includes a recent manufacturing of GMP production of clinical trial material, successful completion of an FDA pre-submission meeting, and positive preclinical data demonstrating effective al

Raanana, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the successful production of a Good Manufacturing Practice (GMP) batch of clinical trial material (CTM) for its lead product candidate. This milestone follows the Company's previously announced manufacturing agreement with Eurofins CDMO AmatsiAquitaine S.A.S, a leading global GMP CDMO, established to support the supply of clinical trial material for Polyrizon's clinical development program. The GMP manufacturing milestone represents a key step in Polyrizon's clinical deve

Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product. The study was conducted at the University of Parma's Biopharmanet-TEC research center under the scientific supervision of Prof. Fabio Sonvico. The laboratory specializes in the research and development of intranasally administered technologies. The evaluation was performed using a validated silicone nasal cast model (Koken® LM

HONG KONG, Feb. 17, 2026 /PRNewswire/ -- Early in 2026, Polyrizon Ltd. (NASDAQ:PLRZ), a pre-clinical-stage biotechnology company developing intranasal protective solutions, completed the branding process for its lead intranasal allergy product, formerly known as PL-14, now officially named NASARIX™. This included trademark screening in the U.S. and European markets and represents a practical step toward potential commercialization for the pre-clinical-stage Israeli biotech. Polyrizon is assessing whether NASARIX™ could emerge as a meaningful advancement in allergy treatment.The Allergic Rhinitis ChallengeAllergic rhinitis- often called hay fever- remains a widespread and burdensome condition

The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDA Raanana, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, recently announced the signing of a non-binding Memorandum of Understanding (MOU) with Arrow Aviation Ltd. ("Arrow Aviation"), a global private aviation company. Under the terms of the MOU, Polyrizon intends to acquire a 51% stake in Arrow Aviation on a fully diluted basis through a cash in

6-K - Polyrizon Ltd. (0001893645) (Filer)

424B5 - Polyrizon Ltd. (0001893645) (Filer)

20-F/A - Polyrizon Ltd. (0001893645) (Filer)

20-F - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

SCHEDULE 13G/A - Polyrizon Ltd. (0001893645) (Subject)

6-K - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company's preparations towards its clinical trial for PL-14 that is expected to commence in 2025. Dr. Meir brings over a decade of experience in the medical device and pharmaceutical industries, with a proven track record in regulatory strategy, clinical affairs management and product developmen

Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins' Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). This strategic appointment reflects Polyrizon's ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions. Asaf Azulay brings over 20 years of extensive experience in the medical devices industry, with expertise in leading quality teams and i